Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 11, 2023
Finance

Menlo Ventures continues scaling focus on tech-enabled bio 

Menlo is looking to invest in generative AI for drug design and problem-solvers for gene editing — and to grow its healthcare team
BioCentury | May 26, 2022
Product Development

Early promise for Enterome’s microbiome-derived cancer vaccine

ASCO data show 54.5% ORR for EO2401/Opdivo/Avastin combo in glioblastoma
BioCentury | Mar 9, 2018
Financial News

Oxford Vacmedix raises $12.5M series A

BioCentury | Mar 6, 2018
Financial News

Oxford Vacmedix raises $12.5M series A

BioCentury | Sep 13, 2017
Distillery Therapeutics

Infectious disease

BioCentury | Jun 7, 2017
Distillery Therapeutics

Cancer

Items per page:
1 - 10 of 40